View Item 

Show simple item record

Immunophenotypic switch in cutaneous T‐cell lymphoma: A series of three cases and review of the literature
dc.contributor.authorBitar, Carole
dc.contributor.authorHile, Grace
dc.contributor.authorBrown, Noah A.
dc.contributor.authorFullen, Douglas R.
dc.contributor.authorLowe, Lori
dc.contributor.authorTejasvi, Trilokraj
dc.contributor.authorWilcox, Ryan A.
dc.contributor.authorHarms, Paul W.
dc.contributor.authorChan, May P.
dc.contributor.authorBresler, Scott C.
dc.contributor.authorHristov, Alexandra C.
dc.date.accessioned2021-07-01T20:10:25Z
dc.date.available2022-08-01 16:10:21en
dc.date.available2021-07-01T20:10:25Z
dc.date.issued2021-07
dc.identifier.citationBitar, Carole; Hile, Grace; Brown, Noah A.; Fullen, Douglas R.; Lowe, Lori; Tejasvi, Trilokraj; Wilcox, Ryan A.; Harms, Paul W.; Chan, May P.; Bresler, Scott C.; Hristov, Alexandra C. (2021). "Immunophenotypic switch in cutaneous T‐cell lymphoma: A series of three cases and review of the literature." Journal of Cutaneous Pathology 48(7): 986-994.
dc.identifier.issn0303-6987
dc.identifier.issn1600-0560
dc.identifier.urihttps://hdl.handle.net/2027.42/168258
dc.description.abstractPrimary cutaneous T‐cell lymphoma (CTCL) comprises a heterogeneous group of neoplasms with variable clinical behavior. Immunophenotypic switch (IS) is a phenomenon that occurs during lymphoma progression and is defined by an alteration in the immunophenotypic expression of a tumor with retention of its genotypic signature. This has been well‐recognized in hematopoietic neoplasms; however, it has been rarely reported in CTCL and its clinical implications are not well understood. We present the clinical, histopathologic, immunophenotypic, and genetic findings of three cases of CTCL that demonstrated IS post treatment with variable outcomes. We add our cases to the small number previously reported to increase awareness of this phenomenon and its diagnostic challenge.
dc.publisherWiley Periodicals, Inc.
dc.publisherBlackwell Publishing Ltd.
dc.subject.othercutaneous T‐cell lymphoma
dc.subject.otherT‐cell receptor gene rearrangement
dc.subject.otherimmunophenotypic switch
dc.subject.otherimmunophenotype
dc.subject.otherimmunohistochemistry
dc.titleImmunophenotypic switch in cutaneous T‐cell lymphoma: A series of three cases and review of the literature
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDermatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168258/1/cup14026.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168258/2/cup14026_am.pdf
dc.identifier.doi10.1111/cup.14026
dc.identifier.sourceJournal of Cutaneous Pathology
dc.identifier.citedreferenceAgbay RL, Torres‐Cabala CA, Patel KP, et al. Immunophenotypic shifts in primary cutaneous gammadelta T‐cell lymphoma suggest antigenic modulation: a study of sequential biopsy specimens. Am J Surg Pathol. 2017; 41 ( 4 ): 431 ‐ 445.
dc.identifier.citedreferenceAung PP, Climent F, Muzzafar T, et al. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T‐cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014; 41 ( 1 ): 51 ‐ 57.
dc.identifier.citedreferenceVargas Nevado A, Lopez Navarro N, Gallego Dominguez E, Herrera Ceballos E. Immunophenotypic shift associated with angiocentricity and cytoxic characteristics in a case of mycosis fungoides. Actas Dermosifiliogr. 2016; 107 ( 8 ): 697 ‐ 699.
dc.identifier.citedreferenceKreuter A, Altmeyer P. Rapid onset of CD8+ aggressive T‐cell lymphoma during bexarotene therapy in a patient with Sezary syndrome. J Am Acad Dermatol. 2005; 53 ( 6 ): 1093 ‐ 1095.
dc.identifier.citedreferenceOkada S, Nannya Y, Ota S, et al. Cutaneous T‐cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant. Br J Dermatol. 2010; 162 ( 1 ): 229 ‐ 230.
dc.identifier.citedreferenceNikolova M, Echchakir H, Wechsler J, Boumsell L, Bensussan A, Bagot M. Isolation of a CD8alphaalpha+ CD4– tumour T‐cell clone with cytotoxic activity from a CD4+ CD8– cutaneous T‐cell lymphoma. Br J Dermatol. 2003; 148 ( 1 ): 24 ‐ 29.
dc.identifier.citedreferenceEndo C, Naka Y, Miyagaki T, et al. Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides. Br J Dermatol. 2016; 175 ( 4 ): 830 ‐ 833.
dc.identifier.citedreferenceMarks E, Shi Y, Wang Y. Two cases of phenotypic switch of primary cutaneous T cell lymphoma after treatment with an aggressive course and review of the literature. Virchows Arch. 2019; 475 ( 5 ): 637 ‐ 648.
dc.identifier.citedreferencePui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 1991; 78 ( 5 ): 1327 ‐ 1337.
dc.identifier.citedreferenceBraue JA, Daniels AB, Zwerner JP, Kim SJ, Zic JA. Intraocular involvement of mycosis fungoides associated with immunophenotypic switch from CD4(+) to CD8(+). Blood. 2018; 131 ( 8 ): 932 ‐ 935.
dc.identifier.citedreferenceKitadate A, Ikeda S, Abe F, et al. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4‐positive mature T‐cell lymphomas. Haematologica. 2018; 103 ( 1 ): 126 ‐ 135.
dc.identifier.citedreferenceSeliem RM, Freeman JK, Steingart RH, Hasserjian RP. Immunophenotypic changes and clinical outcome in B‐cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006; 14 ( 1 ): 18 ‐ 23.
dc.identifier.citedreferenceNielson C, Fischer R, Fraga G, Aires D. Loss of CD30 expression in anaplastic large cell lymphoma following brentuximab therapy. J Drugs Dermatol. 2016; 15 ( 7 ): 894 ‐ 895.
dc.identifier.citedreferenceGoyal A, Patel S, Goyal K, Morgan EA, Foreman RK. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol. 2019; 46 ( 11 ): 823 ‐ 829.
dc.identifier.citedreferenceBonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T‐cell receptor molecules or molecules of proximal T‐cell receptor signaling. Blood. 2004; 104 ( 10 ): 3358 ‐ 3360.
dc.identifier.citedreferenceJothishankar B, Venkataraman G, Goldberg RC, Abdulla F. Heterogeneity of T‐cell receptor expression at transformation in mycosis fungoides/Sezary syndrome (MF/SS). Ann Diagn Pathol. 2019; 43: 151404.
dc.identifier.citedreferenceDaniels J, Doukas PG, Martinez‐Escala ME, et al. Cellular origins and genetic landscape of cutaneous gamma delta T‐cell lymphomas. Nat Commun. 2020; 11 ( 1 ): 1806.
dc.identifier.citedreferenceGuitart J, Martinez‐Escala ME, Subtil A, et al. Primary cutaneous aggressive epidermotropic cytotoxic T‐cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol. 2017; 30 ( 5 ): 761 ‐ 772.
dc.identifier.citedreferenceSwerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, Francee: IARC; 2017.
dc.identifier.citedreferenceTschetter AJ, Zafar F, Moye MS, et al. CD20(+) cutaneous T‐cell lymphoma with phenotypic shift after treatment with rituximab: case report and review of the literature. JAAD Case Rep. 2020; 6 ( 4 ): 308 ‐ 310.
dc.identifier.citedreferenceVermeer MH, Geelen FA, Kummer JA, Meijer CJ, Willemze R. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol. 1999; 154 ( 10 ): 1203 ‐ 1210.
dc.identifier.citedreferenceLois N, Hiscott PS, Nash J, Wong D. Immunophenotypic shift in a case of mycosis fungoides with vitreous invasion. Arch Ophthalmol. 2000; 118 ( 12 ): 1692 ‐ 1694.
dc.identifier.citedreferenceJohnson WT, Leeman‐Neill RJ, Patel P, et al. Fatal case of primary cutaneous aggressive T‐cell lymphoma switching from a CD4+ to a CD8+ phenotype: progressive disease with bexarotene and romidepsin treatment. Am J Dermatopathol. 2016; 38 ( 11 ): 832 ‐ 837.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cup14026.pdf
Size:
20.82MB
Format:
PDF
View/Open
Name:
cup14026_am.pdf
Size:
18.59MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.